Seres Therapeutics, Inc. 4
4 · Seres Therapeutics, Inc. · Filed Jul 28, 2016
Insider Transaction Report
Form 4
Trucksis Michele
Chief Medical Officer and EVP
Transactions
- Exercise/Conversion
Common Stock
2016-07-27$15.77/sh+38,064$600,269→ 38,064 total - Sale
Common Stock
2016-07-27$35.14/sh−38,064$1,337,512→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2016-07-27+38,064→ 301,060 totalExercise: $15.77Exp: 2025-03-24→ Common Stock (38,064 underlying)
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.10 to $35.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option vested as to 25% of the shares on January 15, 2016. The remainder of the shares will vest in 12 equal quarterly installments thereafter.